<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5185">
  <stage>Registered</stage>
  <submitdate>17/08/2015</submitdate>
  <approvaldate>17/08/2015</approvaldate>
  <nctid>NCT02527200</nctid>
  <trial_identification>
    <studytitle>Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome</studytitle>
    <scientifictitle>Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-004415-37</secondaryid>
    <secondaryid>NN8022-4179</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolism and Nutrition Disorder</healthcondition>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Learning disabilities</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - liraglutide
Treatment: drugs - placebo

Experimental: Liraglutide - 

Placebo Comparator: Placebo - 


Treatment: drugs: liraglutide
Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.

Treatment: drugs: placebo
Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in body mass index (BMI) standard deviation score (SDS)</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in body mass index (BMI) standard deviation score (SDS)</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent of subjects achieving equal to or above 5% reduction in baseline BMI</outcome>
      <timepoint>At weeks 16 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent of subjects achieving equal or above 10% reduction in baseline BMI</outcome>
      <timepoint>At weeks 16 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in body mass index (BMI)</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in body mass index (BMI)</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body weight (kilogram (kg), pounds (lb) and percent (%))</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body weight (kilogram (kg), pounds (lb) and percent (%))</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperphagia total score</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperphagia total score</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>hyperphagic behaviour score</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>hyperphagic behaviour score</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperphagia drive score</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperphagia drive score</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperphagia severity score</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hyperphagia severity score</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Systolic and diastolic blood pressure</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Systolic and diastolic blood pressure</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Glycosylated Haemoglobin (HbA1c)</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Glycosylated Haemoglobin (HbA1c)</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting plasma glucose (FPG)</outcome>
      <timepoint>Week 0, Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting plasma glucose (FPG)</outcome>
      <timepoint>Week 0, Week 52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Confirmed diagnosis of PWS (Prader-Willi Syndrome) (by genetic testing)

          -  Male or female, age at the time of signing informed consent: - Part A: above or equal
             to 12 years and less than 18 years

          -  Tanner stage 2-5 pubertal development for part A, and Tanner stage 1 for part B

          -  BMI (body mass index) corresponding to equal or above 30 kg/m^2 for adults by
             international cut-off points1 and equal or above the 95th percentile for age and sex
             (for diagnosis of obesity)

          -  Stable body weight during the previous 90 days before screening ( below 10 kg
             self-reported weight change)

          -  Testing has been performed to evaluate for adrenal insufficiency and documented in
             medical record</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Type 1 diabetes mellitus (T1DM)

          -  Type 2 diabetes mellitus (T2DM)

          -  Calcitonin equal or above 50 ng/L

          -  No change in treatment plan with growth hormone (GH) from randomisation to the end of
             the open-label period patients on growth hormone to stay on, patients off GH to stay
             off during this period. Adjustments in doses of growth hormone will be permitted)

          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary
             Thyroids Carcinoma (MTC)

          -  History of pancreatitis (acute or chronic)

          -  Treatment with any medication prescribed for weight loss within 90 days before
             screening (e.g. orlistat, zonisamide, topiramate/phentermine, lorcaserin, phentermine,
             bupropion/naltrexone,liraglutide, metformin)

          -  Untreated adrenal insufficiency

          -  Suggestive history of, or significant risk of gastroparesis (e.g. marked abdominal
             bloating post meal, history of vomiting, severe constipation), as judged by the
             Investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>9/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>10/08/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Camperdown</hospital>
    <hospital>Novo Nordisk Investigational Site - Parkville</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>ANGERS cedex 09</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>BRON cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Haguenau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>MARSEILLE Cédex 05</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>MONTPELLIER cedex 05</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Fiumicino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Samsun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Trabzon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted globally. The aim of this trial is to investigate the effect of
      liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02527200</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Novo Nordisk</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@novonordisk.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>